Effects of a resurgence in COVID-19 cases on future pharma business planning

White Paper

Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning

Fears have arisen regarding a resurgence in COVID-19 cases. Numerous factors could be contributing to a resurgence in COVID-19 cases. Some suggest it is because more tests are bein ...

COVID-19 Recession Effects on Pharmaceutical Patient Health Outcomes

White Paper

COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes

This white paper investigates the research framework to model the expected effects on the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceuti ...

Coronavirus Pandemic Effects On Incentive Compensation

White Paper

Coronavirus Pandemic Effects On Incentive Compensation

This paper focuses on coronavirus pandemic effects on IC for pharma companies in the short-term, medium-term, and long-term, while also providing prescriptive actions for sales exe ...

Patient-Centric Commercial Strategy

White Paper

Designing A Patient-Centric Commercial Strategy

This whitepaper addresses how RWE should be leveraged for informing various commercial decisions with a deeper-dive into marketing-mix analysis (MMx). ...

Coronavirus Pandemic US Pharmaceutical Industry

White Paper

How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry?

The outbreak of the coronavirus pandemic illustrates the inherent risks and uncertainties that are prevalent in the operation of complex and global business, as seen in the pharmac ...

Corona Virus White Paper

White Paper

Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?

Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...

Importation of Drugs

White Paper

Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary

This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader e ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

White Paper

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...

US Recession Pharma Analytics

White Paper

How Will The Next Great Recession Affect The US Pharma Industry?

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...

Merger and Acquisitions

White Paper

Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 2

Learn what several senior pharma commercial operations leaders think of the potential implications of industry challenges on business operations, sales and marketing objectives and ...

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

White Paper

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 1

The pharmaceutical industry is in a state of flux with the increasing influence of payers, pressure from the government with restricted healthcare budgets, and the rise of multi-ch ...

PBMs Pharma Benefit Manager

White Paper

Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs

This white paper looks at how rebates to PBMs relate to drug prices from two perspectives: how they are supposed to work versus what actually happens. ...

Growing Attention Being Paid To Pharma Company Rebates And Discounts

White Paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

White Paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

Perspectives On Pharma Company Use Of Open Payments Data

White Paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

How Regulatory Changes Are Driving The Future Of The Medical Device Industry

Report

How Regulatory Changes Are Driving The Future Of The Medical Device Industry

With new entrants from emerging countries giving the established brands a run for their money, the medical device market has become more competitive. ...

The Causes and Solutions of Chronic Drug Shortages in the United States

White Paper

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

White Paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

White Paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

Traditional Call Planning

Blog

Quantifying The Economic Burden Of Inadequate Symptom Control Among Patients With IBS-D

Axtria recently collaborated on a study to analyze the “Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome wit ...

Traditional Call Planning

Blog

Insightful HEOR Analysis For The Cardiovascular Community

Some of the most rewarding work we are involved in at Axtria right now is in the Health Economics and Outcomes Research (HEOR) space, where we are partnering with our clients to ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

Blog

Quantifying The Economic Burden Of IBS-D

As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and e ...

Decision Science Asset Diversification Versus Concentration

White Paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...

The Reasons for and Solutions to Chronic Drug Shortages in the United States

White Paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

Pricing and Market Effects of Biosimilar Entry in the US

White Paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

White Paper

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...

State Of Commercial Excellence 2017 - Part 1

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

White Paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

Make US Pharma Great Again!? - Part 1

White Paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Econometric Analysis Of Biopharmaceutical Transfer Pricing

White Paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

White Paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

Patient Claims Versus EHR Data – How To Choose Between The Two?

White Paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

The Relationship Between Drug Price Controls And Patient Health Outcomes

White Paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

White Paper

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

White Paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand - Generic Drug Utilization

White Paper

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds emp ...

White Paper

Measuring Sales Rep-Physician Relationship Disruption In Sales Force Optimization & Territory Alignment

There is a growing importance of maintaining sales rep-physician relationships and accounting for their disruption in sales force optimization and territory alignment analyses. Thi ...

Biosimilars In The US - Will They Deliver On The Promise?

Blog

Biosimilars In The US – Will They Deliver On The Promise?

Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...

White Paper

Driver Score – The New Paradigm

Of late, telematics as a disruptive technology is rapidly gaining attention in shaping the future. New industries are accepting this revolution and are moving to data-backed decisi ...

White Paper

At Supplier Management Crossroads? – Choose The Right Approach

Of late, regulators have started focusing attention on the way banks and financial institutions are managing the risk in their supplier management programs. ...

White Paper

Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems

There has been an immense improvement of theory and algorithms in recent times leading to enhancement in computation power. Also, online data availability was never easier than now ...

White Paper

A Mathematical Framework For Privacy Risk

In recent trends, people’s attitude towards the internet has changed tremendously. The willingness and comfort level of people to share and reveal information about themselves an ...

The Pricing Challenge Of Pharma's Shift To Specialty Medicines

White Paper

The Pricing Challenge Of Pharma’s Shift To Specialty Medicines

The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift ...

White Paper

Operational Risk Management In Banks

In recent years, more than 100 losses exceeding US$ 100 million have been reported, prompting the regulators to turn their focus towards effectiveness of Operational Risk Managemen ...

White Paper

Basel Downturn – Identification & Estimation

As part of Basel accords, banks and other financial institution should hold sufficient capital to buffer against large unexpected losses. Minimum capital required, for pillar 1, is ...

White Paper

Borrower Centrism- Bring ‘Service’ Back Into Mortgage Servicing

Mortgage Servicers are entrusted with almost all vital operations, ranging from payment collection to loss mitigation attempts. However, until January 2014, no strict regulations w ...

White Paper

Behavioural Segment Based Stress Testing Using Markov Chain

Stress testing involves assessing a bank’s ability to stay solvent in case of ‘stressed’ macro-economic scenarios. Banks are expected to create a response mechanism in case a ...

White Paper

Claim Operations Optimization

Processing claims quickly and accurately is one of the biggest challenges payers face today. Huge volume of claims notwithstanding, multiple and incompatible systems requiring sign ...

White Paper

Evolution Of SDLC

Today, more than ever before, success or failure of a banking enterprise abides a direct correlation towards its ability to meet the demanding time to market conditions. ...

White Paper

Enabling Smarter Commercial Model Experimentation

The pharmaceutical industry is changing and manufacturers need to modify approaches and structures to survive in a competitive environment. ...

White Paper

Portfolio Stress Testing Methodologies

As the world is crawling out of the global economic crisis, several efforts are underway by regulators as well as international organizations, such as the International Monetary Fu ...

White Paper

Linking Customer Focus With Business Performance

The concept of the ‘customer-centric business’ is pervasive, with companies small and large, across every industry, making efforts to improve customer focus. ...

White Paper

Risk Basel Methodology Implementation

Basel will have significant impact on the banking sector. One recent study1 estimated that as the Basel rules are written today; by 2019 the US banks will need about $870 billion o ...

White Paper

Is Channel ROI Dead?

From broadcasting a series of monologues at ‘easy’ customers in order to sell products, to having an engaging and effective dialogue with fairly ‘complex’ targets to make m ...

White Paper

Improve STAR Rating With Analytics Powered Therapy Adherence Strategy

Improving the quality of care and services to patients and enrollees is one of the key imperatives of Affordable Care Act (ACA). Several initiatives and measures have been put in p ...

White Paper

Operational Risk Computation Methodology

Operational Risk has become a key area of priority for the banks in the recent past due to regulatory pressures. The banks are identifying ways of measuring, monitoring, and predic ...

White Paper

Mortgage Servicer – You’ve Got Information!

In the wake of the crisis, the mortgage industry has been under pressure to reform the way loans are underwritten and serviced. In particular, there is significant regulatory press ...

White Paper

Payer Influence On Product Performance In Pharmaceutical Industry

Payers vary in their ability to assert formulary compliance. We will explore how tools and analytics can enable a pharmaceutical manufacturer to assess factors impacting formulary ...

White Paper

Telematics – Watching Your Every Move

With the US economic recovery, miles driven have also been showing a positive trend lately. What does all this mean? More cars, more miles, and more traffic on the road – all put ...

White Paper

Effective Quality Assurance For Banks

Banks are deploying more advanced technologies and online systems, including internet banking systems, mobile banking and payment systems, online trading platforms etc. to meet the ...

White Paper

From “Sick” Care To “Health” Care: Analytics Driven Transformation

Globally, healthcare continues to focus on treating disease.  More reactive ‘sick care’ than proactive ‘healthcare’! This approach basically leads to intervention only whe ...

White Paper

Account Based Models In An Institutional Setting

The stakeholders and factors that drive the ultimate prescribing of a medication have shifted considerably since the turn of the century. ...

White Paper

The Recent Woes Of Non-Bank Mortgage Servicers

Non-bank mortgage servicers have grown by leaps and bounds since the crisis. As they have become an integral part of the American dream of home ownership, they have also attracted ...